[Therapeutic effects on disorders of spermatogenesis in hyperprolactinemia without pituitary adenoma].
As in patients with high pituitary prolactin secretion disturbances of the spermatogenesis are observed, we picked out from our patients with low sperm count those showing hyperprolactinemia without pituitary adenoma. They were treated for 50 days with 2-brom-alpha-ergocryptin (Pravidel, Sandoz AG, Nürnberg), which selectively inhibits prolactin release. Following treatment, in 7 cases an increase in sperm count was observed, while in 2 cases a decrease occurred. 4 cases with azoospermia showed no alteration. No explanation for the possible stimulation of spermatogenesis can be given today.
D004873:Ergolines / Q000627:therapeutic use; D006801:Humans; D007248:Infertility, Male / Q000188:drug therapy; D008297:Male; D011388:Prolactin / Q000097:blood*; D013091:Spermatogenesis / Q000187:drug effects*
D004873:Ergolines; D011388:Prolactin
Therapeutische Beeinflussbarkeit von Spermatogenese-Störungen bei Hyperprolaktinämie ohne Hypophysenadenom.